Ondansetron
Zofran
Ondansetron (Zofran) is a metabolic & fat loss research compound. 5-HT3 receptor antagonist — blocks serotonin signaling at the vagal afferents and the chemoreceptor trigger zone, which is the pathway GLP-1 nausea travels down.
Ondansetron quick facts
| Reported research dose | 4–8mg as needed |
| Route | Oral / ODT |
| Frequency | Up to 3x · As needed |
| Half-life | ~4 hours |
| Forms | Oral |
| Evidence level | Approved for chemotherapy and post-operative nausea |
The practical reason it's here: GLP-1 nausea is the number one reason people abandon semaglutide or tirzepatide in the first month, and it's treatable rather than something to endure. The dissolvable tablet works when you can't keep anything down. ⚠️ Prolongs QT — caution with other QT-prolonging drugs. Constipating, which stacks badly with the GLP-1 itself.
How Ondansetron works
5-HT3 receptor antagonist — blocks serotonin signaling at the vagal afferents and the chemoreceptor trigger zone, which is the pathway GLP-1 nausea travels down.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Where to get Ondansetron
Buy Ondansetron at AlgoRx →The evidence for Ondansetron
Graded by what exists behind each claim.
✅ Clinically validated
- Approved with extensive trial data for chemotherapy-induced, radiation-induced and post-operative nausea. One of the more clearly effective drugs in medicine for its actual indication.
- QT prolongation is the established risk — the FDA withdrew the 32 mg intravenous dose over it. That is a dose-specific regulatory action, not a reason to avoid ordinary dosing, but it is why it should not be casually combined with other QT-prolonging drugs.
📊 Correlative data
- Very wide use. In this Vault it appears mainly as the answer to GLP-1 nausea, which is a legitimate and common off-label use — and one where the constipating effect compounds a problem GLP-1 agonists already cause.
🧪 Theoretical / extrapolated
- A 5-HT3 receptor antagonist. Chemotherapy and gastric irritation cause enterochromaffin cells in the gut to release serotonin, which activates 5-HT3 receptors on vagal afferents and triggers the vomiting reflex in the area postrema.
- Blocking the trigger rather than sedating the patient is why it replaced older antiemetics — no dopamine blockade means no extrapyramidal effects and no sedation.
- It blocks the signal, not the cause. Used against GLP-1 nausea it suppresses a symptom arising from delayed gastric emptying, and the delayed emptying continues.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Ondansetron actually does
The 5-HT3 receptor is the odd one out among serotonin receptors, and that fact explains everything ondansetron does. Every other serotonin receptor is a G-protein-coupled receptor signaling through second messengers over seconds. 5-HT3 is a ligand-gated cation channel — a pentameric Cys-loop receptor in the same structural family as the nicotinic acetylcholine receptor. Serotonin binds, the pore opens, sodium and calcium enter, the neuron depolarizes. Milliseconds, not seconds. Ondansetron is a selective antagonist at that channel Ye 2001, which means it is blocking a fast synaptic event rather than modulating a tone.
Where the channel is, and why that is two places. The emetic reflex ondansetron interrupts starts in the gut: enterochromaffin cells in the intestinal mucosa release serotonin when the mucosa is injured or irritated, and that serotonin acts on 5-HT3 channels on vagal afferent terminals in the gut wall. The signal travels to the nucleus tractus solitarius. In parallel, 5-HT3 receptors sit in the area postrema, the chemoreceptor trigger zone, a circumventricular structure that lies outside the blood-brain barrier. Blocking both the peripheral trigger and the central relay is why the class works where dopamine antagonists do not Tyers 1992.
The vagal half is not theoretical, and there is a human trial that isolates it. Faris 2000 used ondansetron explicitly to decrease afferent vagal activity in a randomized, double-blind trial in bulimia nervosa, and reported reduced symptoms. That is direct human evidence that the drug turns down vagal afferent traffic and that doing so changes ingestive behavior — a mechanism worth holding onto on a page where the reason for listing this drug is GLP-1 nausea.
And here is where the extrapolation has to be labeled as one. GLP-1 receptor agonists cause nausea by a route that is only partly the same. They slow gastric emptying, and they act on GLP-1 receptors in the area postrema directly. So the brainstem node is shared and the trigger is not: GLP-1 nausea does not begin with enterochromaffin serotonin release the way chemotherapy nausea does. The mechanistic prediction that follows is partial efficacy — better than nothing because the relay is shared, worse than in chemotherapy because the input is not. Nobody has tested that, and saying so is more useful than assuming either answer.
Cell, rodent, human — and where it stops
In animals. The class was characterized in ferret and dog emesis models, where 5-HT3 antagonists abolished vomiting provoked by cytotoxic drugs and radiation, and the mechanistic work localized the action to vagal afferents and the area postrema Tyers 1992.
In humans, for its own indication: about as good as drugs get. Ondansetron is approved for chemotherapy-induced, radiation-induced and postoperative nausea and vomiting on extensive randomized data US Food and Drug Administration 2025. There is no argument to have here; this is one of the more clearly effective drugs in medicine for the thing it is licensed for.
In humans, for a vagal-afferent endpoint. Faris 2000 is a randomized double-blind trial in bulimia nervosa — a completely different clinical question, chosen because it isolates the vagal mechanism rather than the emetic one.
In humans, for safety at scale. Huybrechts 2018 followed 1,816,414 pregnancies, of which 88,467 (4.9%) had first-trimester ondansetron exposure. Cardiac malformations: adjusted relative risk 0.99 (95% CI 0.93–1.06) — no association. Oral clefts: adjusted relative risk 1.24 (95% CI 1.03–1.48), an absolute risk difference of 2.7 per 10,000 births. That is what a real, small, honest signal looks like when it is measured properly, and both halves of it belong in the same sentence.
The obstacle, and it is the reason this compound is on this site at all. The indication people here want is GLP-1-induced nausea, and there is no randomized trial of ondansetron for it. Not a small one, not an underpowered one — none. The case rests entirely on the shared brainstem relay described above, and on the observation that it is cheap, familiar and available as a tablet that dissolves when you cannot keep water down. That is a reasonable clinical bet and it is not evidence, and a site claiming to be the epicenter of this information should say which one it is.
Ondansetron pharmacokinetics — how much of it actually gets in
Route: oral, and the numbers are all in the label. Oral bioavailability after a single 8 mg tablet is approximately 56%, Tmax is 2.0 to 2.2 hours, mean elimination half-life is 3.1 to 4.9 hours in adults, and protein binding is 70% to 76% US Food and Drug Administration 2025. In people aged 75 and over the half-life stretches to 4.5 to 6.2 hours.
That 56% is first-pass, and it sets up the most common misunderstanding about this drug. The orally disintegrating tablet is not a sublingual tablet. It disintegrates on the tongue and is then swallowed with saliva and absorbed from the gastrointestinal tract like any other oral dose — it solves the problem of not being able to swallow a tablet, not the problem of first-pass metabolism. Its usefulness in someone actively vomiting is real; its pharmacokinetic advantage is not.
What degrades it, and why one enzyme matters more than the others. Ondansetron is cleared by hepatic oxidation through CYP1A2, CYP2D6 and CYP3A4, with CYP3A4 playing the predominant role US Food and Drug Administration 2025. Redundancy across three enzymes is normally protective — and it is, for interactions. The exception is CYP2D6, because that gene is wildly polymorphic. People carrying extra functional copies (ultrarapid metabolizers) clear ondansetron fast enough that a standard dose can simply fail, and the CPIC pharmacogenetics guideline for CYP2D6 and ondansetron exists for precisely that reason Bell 2017. If a normal dose does nothing for you, that is a real and testable explanation rather than bad luck.
The dose ceilings that come out of the pharmacokinetics. In severe hepatic impairment (Child-Pugh 10 or above) clearance falls far enough that the label caps the total daily dose at 8 mg US Food and Drug Administration 2025. And by the intravenous route the ceiling is not about clearance at all but about the heart: FDA announced on 4 December 2012 that the 32 mg single intravenous dose would no longer be marketed because of cardiac risk, and that no single intravenous dose should exceed 16 mg, with 0.15 mg/kg every 4 hours for three doses as the alternative regimen US Food and Drug Administration 2012.
What would have to be true, and how you would know it was not
1. The QT effect should be dose-dependent and electrolyte-dependent, and that makes it manageable rather than mysterious. The regulatory action was taken against a 32 mg intravenous dose, not against 4 or 8 mg by mouth US Food and Drug Administration 2012. Prediction: at oral doses, in someone with normal electrolytes and no other QT-prolonging drug, QTc moves by an amount that does not matter. The amplifiers are what to measure — a CMP for potassium and a magnesium (serum) level before starting, if you are on a diuretic, vomiting repeatedly, or taking another QT-prolonging drug. Low potassium or low magnesium is what turns a small QT effect into a clinical one.
2. The prediction that cuts against the reason it is listed here: constipation should get worse, and predictably. Blocking 5-HT3 slows colonic transit — that is not a side effect, it is the mechanism by which this class treats diarrhea-predominant irritable bowel. Stack it on a GLP-1 agonist, which already slows gastric and intestinal transit, and the two effects add. Prediction: measurable worsening of stool frequency and form within 1 to 2 weeks of regular use. Track it — a stool diary is free — because swapping nausea for constipation is a real trade, not a hypothetical.
3. Efficacy against GLP-1 nausea should be partial, not complete. The shared node is the area postrema; the trigger is not enterochromaffin serotonin. So the prediction is a reduction in nausea intensity without abolition, and little effect on the early satiety and fullness that come from delayed gastric emptying. If someone reports complete resolution of all GLP-1 gastrointestinal symptoms on 4 mg, the more likely explanation is that the dose escalation week passed.
4. Complete non-response at a standard dose is a testable hypothesis. CYP2D6 ultrarapid metabolism Bell 2017. A pharmacogenetic panel is an ordinary, purchasable test, and the guideline's recommendation for an ultrarapid metabolizer is to use a different antiemetic rather than a bigger dose — which matters, because a bigger dose is the intuitive move and it is the one that walks toward the QT problem.
What nobody has tested yet
Nobody has run a randomized trial of ondansetron for GLP-1-induced nausea. This is the single most useful missing trial on this entire site, and it is not a hard one: a hundred people starting semaglutide or tirzepatide, randomized to 4 mg orally disintegrating as needed or matching placebo through the first twelve weeks, with discontinuation of the GLP-1 as the primary endpoint rather than a nausea score. Discontinuation is the outcome that actually matters, it is unambiguous, and the whole rationale for combining these two drugs stands or falls on it.
Nobody has separated the two GLP-1 nausea pathways in a person. Delayed gastric emptying and direct area postrema activation both produce nausea and imply different treatments — a prokinetic for one, a central antiemetic for the other. A gastric-emptying study (scintigraphy or a breath test) alongside symptom scores, with and without ondansetron, would say which component the drug touches. Nobody has done it, and until somebody does, the choice between antiemetic and prokinetic is a guess.
Nobody has quantified the constipation interaction. Two drugs that independently slow gut transit, taken together, by a very large number of people right now. Whole-gut transit time with a wireless motility capsule, on a GLP-1 alone versus a GLP-1 plus regular ondansetron, in twenty people, would produce the number that should govern how freely this combination is recommended.
And nobody has prospectively tested CYP2D6-guided antiemetic choice for a hard outcome. Bell 2017 is a guideline built on pharmacokinetics and observational data. Genotype first, then randomize ultrarapid metabolizers to ondansetron or an alternative, with rescue-medication use as the endpoint. It would settle whether a test people can already buy changes anything.
Ondansetron — its own safety story, not its class's
The QT story, told accurately, because the usual version is wrong in both directions. FDA did not withdraw ondansetron and did not restrict ordinary dosing. On 4 December 2012 it announced that the 32 mg single intravenous dose would no longer be marketed because of the potential for serious cardiac risk, that no single intravenous dose should exceed 16 mg, and that 0.15 mg/kg every 4 hours for three doses remained an appropriate regimen US Food and Drug Administration 2012. The current label carries QT prolongation as a Warning and Precaution, notes postmarketing reports of torsade de pointes, and says to avoid ondansetron in congenital long QT syndrome US Food and Drug Administration 2025. The risk is real, dose-related, and amplified by low potassium, low magnesium, heart failure, bradyarrhythmia and other QT-prolonging drugs.
The labeled warning nobody on a GLP-1 should skip: masking of progressive ileus and gastric distension. That is a Warning and Precaution in its own right US Food and Drug Administration 2025. An antiemetic taken regularly by someone whose stomach is already emptying slowly can suppress the symptom that would otherwise announce a genuine obstruction or severe gastroparesis. Vomiting is information. Turning it off is useful and it costs you the signal, and the combination this site recommends the drug for is exactly the one where that matters.
Serotonin syndrome, from an antiemetic. The label reports it with 5-HT3 antagonists alone, and most often alongside SSRIs, SNRIs, MAO inhibitors, mirtazapine, fentanyl, lithium, tramadol or intravenous methylene blue US Food and Drug Administration 2025. It is counterintuitive for a drug that blocks a serotonin receptor, and it is in the label.
Pregnancy, with the numbers rather than the headline. In 1.8 million pregnancies, first-trimester ondansetron showed no association with cardiac malformations (adjusted RR 0.99) and a small association with oral clefts (adjusted RR 1.24; absolute difference 2.7 additional cases per 10,000 births) Huybrechts 2018. Both numbers matter: the scare version omits the first, and the reassuring version omits the second.
Two practical items from the label. Myocardial ischemia is listed as a Warning and Precaution; and the orally disintegrating tablet contains phenylalanine — less than 0.03 mg per 4 mg or 8 mg tablet — which matters only to someone with phenylketonuria, but matters absolutely to them US Food and Drug Administration 2025.
Sources read for this page
- Tyers MB, Freeman AJ. Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists.. Oncology 1992 · PMID 1387926
- Ye JH, Ponnudurai R. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders.. CNS Drug Rev 2001 · PMID 11474424
- Bell GC. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.. Clin Pharmacol Ther 2017 · PMID 28002639
- Huybrechts KF. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.. JAMA 2018 · PMID 30561479
- Faris PL. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.. Lancet 2000 · PMID 10711927
- US Food and Drug Administration. ZOFRAN (ondansetron hydrochloride) tablets, oral solution and orally disintegrating tablets - full prescribing information.. FDA approved labeling, revision 2025
- US Food and Drug Administration. FDA Drug Safety Communication: Updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products.. FDA safety communication, 4 December 2012
Ondansetron — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centers. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognized signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumor signal exists in rodents and has not been demonstrated in humans; it is why the labeled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fiber and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Ondansetron — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Ondansetron moves on your bloodwork
Expected direction, not a measured one.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Ondansetron in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Ondansetron
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
Ondansetron — frequently asked questions
What is Ondansetron?
Ondansetron (Zofran) is a metabolic & fat loss research compound. 5-HT3 receptor antagonist — blocks serotonin signaling at the vagal afferents and the chemoreceptor trigger zone, which is the pathway GLP-1 nausea travels down.
Is the full Ondansetron protocol on this page?
The reported research dose is on this page, along with how Ondansetron works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Ondansetron?
Ondansetron has an approximate half-life of ~4 hours, which is part of what determines how often it's dosed.
What's the evidence behind Ondansetron?
Current evidence level: Approved for chemotherapy and post-operative nausea. Ondansetron is offered for research purposes only and is not an approved medicine.
What Ondansetron is used for
Ondansetron appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.